Bedside trial of Covid-19 ICU patients helping doctors pinpoint best treatment

Monash University is a major player in global human trials of a suite of repurposed drugs in critically ill patients from intensive care units – in a bid to outsmart pandemics such as COVID-19.

Researchers are recruiting critically ill COVID-19 patients at the bedside in a unique clinical trial, informing doctors around the globe which medications are providing the most effective treatment, and which ones should be ruled out.

After the 2009 swine flu pandemic claimed around 200,000 lives, the REMAP-CAP trial was set up by a group of intensive care specialists to future-proof for pandemics with intense human trials early in an outbreak. The Minderoo Foundation has today provided $2 million in funding to cover costs associated with staff, resources and materials needed to include patients with COVID-19 in the study.

Click here to read the full story.